IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
IRadimed CorporationNASDAQ: IRMD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $8.22M rose 34.0% year over year, ahead of the +25.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +22.2% a year.
Context
- EBITDA amounted to 36.7% of revenue in FY2025, up 2.4 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $35.18M (+14.4%) for the fiscal year ending Dec 2026, a slowdown from the +22.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.22M-2.2% QoQ
- Last fiscal yearDec 2025
- $30.74M+22.5% YoY
- LTMMar 2026
- $32.23M+25.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +34.0% | -7.9% | -41.9 pp |
| 1 year | +22.5% | +14.4% | -8.1 pp |
| 3-year CAGR | +22.2% | +14.9% | -7.3 pp |
| 5-year CAGR | +14.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 30.74M USD
- Year-over-year change
- +22.5%
- 4-year CAGR
- +28.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.74M | +22.5% |
| FY2024 | 2024-12-31 | 25.09M | +11.5% |
| FY2023 | 2023-12-31 | 22.5M | +33.5% |
| FY2022 | 2022-12-31 | 16.85M | +49.9% |
| FY2021 | 2021-12-31 | 11.24M | — |
EBITDA vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's LTM Mar 2026 EBITDA of $32.23M is the 6th highest of the 11 companies compared; the peer median is $22.59M.
- Its year-over-year change of +25.1% is the 4th highest of 11, against a peer median of -17.5%.
- EBITDA amounts to 37.4% of revenue for IRMD, versus a peer median of 15.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $517.45M | +198.9% | +44.3% | 52.9% |
| LTM Apr 2026 | $462.48M | -25.4% | -7.2% | 16.2% | |
| LTM Mar 2026 | $173.34M | +1.2% | +41.4% | 22.0% | |
| LTM Mar 2026 | $102.9M | -26.8% | -18.1% | 27.5% | |
| LTM Mar 2026 | $57.26M | -9.7% | — | 14.7% | |
| LTM Mar 2026 | $32.23M | +25.1% | +22.2% | 37.4% | |
| LTM Mar 2026 | -$12.08M | +68.8% | — | 5.9% | |
| LTM Sep 2026 | -$21.24M | -198.3% | — | 8.0% | |
| LTM Mar 2026 | -$34.69M | -123.1% | — | 6.0% | |
| LTM Mar 2026 | -$71.9M | +52.3% | — | 7.0% | |
| LTM Mar 2026 | -$289.3M | -260.5% | — | 17.6% | |
| Peer median (excluding IRMD) | $22.59M | -17.5% | +17.1% | 15.4% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 41.81M | 53.3M | 65.56M | 73.24M | 83.81M |
| Cost of Revenue | 9.76M | 12.02M | 15.4M | 16.89M | 19.49M |
| Gross Profit | 32.05M | 41.28M | 50.16M | 56.35M | 64.32M |
| Gross Margin | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% |
| Research & Development | 1.91M | 2.28M | 2.86M | 2.83M | 2.98M |
| Selling, General & Admin | 20.33M | 23.38M | 27.26M | 31.55M | 35.2M |
| Operating Expenses | 22.23M | 25.65M | 30.12M | 34.39M | 38.18M |
| Depreciation & Amortization | 1.41M | 670.67K | 765.18K | 817.66K | 2.38M |
| EBITDA | 11.24M | 16.85M | 22.5M | 25.09M | 30.74M |
| EBITDA Margin | 26.9% | 31.6% | 34.3% | 34.3% | 36.7% |
| Operating Income | 9.82M | 15.63M | 20.04M | 21.96M | 26.15M |
| Operating Margin | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% |
| Interest Income | 34.81K | 581.85K | 1.86M | 2.19M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 18.61K | 553.1K | 1.7M | 2.31M | 2.21M |
| Income Before Tax | 9.84M | 16.18M | 21.74M | 24.28M | 28.36M |
| Pre-Tax Margin | 23.5% | 30.4% | 33.2% | 33.1% | 33.8% |
| Income Tax Expense | 510.82K | 3.35M | 4.55M | 5.04M | 5.88M |
| Net Income | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Net Margin | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
| EPS (Basic) | 0.76 | 1.02 | 1.36 | 1.52 | 1.77 |
| EPS (Diluted) | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 |
| Weighted Avg Shares | 12.35M | 12.56M | 12.6M | 12.67M | 12.72M |
| Weighted Avg Shares (Diluted) | 12.59M | 12.64M | 12.72M | 12.78M | 12.85M |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.